Andhra chief launches probe after malaria tablets cause illness in village

The Hindu reported that a batch of anti‑malaria medication distributed to residents of Gollaguppa village led to a wave of illness, prompting Andhra Pradesh Chief Minister N. Chandrababu Naidu to order a formal inquiry. Seventy‑one villagers received the drugs, and within hours many reported symptoms ranging from nausea to dizziness.

Health officials say 29 of the affected individuals were rushed to the Bhadrachalam Area Hospital, while a further 24 were taken to the Lakshmipuram Primary Health Centre for observation and treatment. The remaining patients are being monitored at home, according to local health workers.

The incident has raised questions about the safety protocols governing mass drug administration (MDA) campaigns in the state. India’s National Vector Borne Disease Control Programme regularly conducts MDA in high‑risk districts to curb malaria transmission, especially in forest‑adjacent areas where the disease remains endemic. Such campaigns typically use Artemisinin‑based combination therapies (ACTs) that are considered safe when administered correctly. However, side‑effects can occur if dosing is inaccurate, if contraindications are ignored, or if the drug supply is compromised.

Historically, Andhra Pradesh has struggled with malaria in its tribal and forest‑border districts. The state has invested heavily in indoor residual spraying, distribution of insecticide‑treated nets, and periodic drug rounds to meet the national goal of malaria elimination by 2030. The current episode underscores the logistical challenges of delivering medicines to remote populations, where literacy levels, local customs, and limited health infrastructure can affect compliance and safety.

The chief minister’s inquiry will examine the procurement, storage, and dispensing procedures of the anti‑malaria tablets, as well as the training of the health workers involved. Preliminary statements from the health department suggest that an internal audit will be completed within two weeks, after which corrective measures will be communicated to the public. Meanwhile, the affected villagers continue to receive supportive care, and the health ministry has urged anyone who received the medication but feels unwell to seek immediate medical attention.

The episode serves as a reminder that while aggressive malaria control can save lives, it must be balanced with rigorous quality assurance to prevent unintended harm. Authorities hope that the investigation will restore confidence in public health initiatives and ensure that future campaigns are both effective and safe.